PKK Library

Your cart is empty.

Welcome to P K Kelkar Library, Online Public Access Catalogue (OPAC)

Protein Tyrosine Kinases (Record no. 502441)

000 -LEADER
fixed length control field 03798nam a22004575i 4500
001 - CONTROL NUMBER
control field 978-1-59259-962-2
003 - CONTROL NUMBER IDENTIFIER
control field DE-He213
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20161121230702.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 100301s2006 xxu| s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781592599622
-- 978-1-59259-962-2
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1385/1592599621
Source of number or code doi
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number QH345
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number QD415-436
072 #7 - SUBJECT CATEGORY CODE
Subject category code PSB
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code SCI007000
Source bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 572
Edition number 23
245 10 - TITLE STATEMENT
Title Protein Tyrosine Kinases
Medium [electronic resource] :
Remainder of title From Inhibitors to Useful Drugs /
Statement of responsibility, etc. edited by Doriano Fabbro, Frank McCormick.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture Totowa, NJ :
Name of producer, publisher, distributor, manufacturer Humana Press,
Date of production, publication, distribution, manufacture, or copyright notice 2006.
300 ## - PHYSICAL DESCRIPTION
Extent XIII, 290 p.
Other physical details online resource.
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
347 ## - DIGITAL FILE CHARACTERISTICS
File type text file
Encoding format PDF
Source rda
490 1# - SERIES STATEMENT
Series statement Cancer Drug Discovery and Development
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Protein Tyrosine Kinases as Targets for Cancer and Other Indications -- Inhibitors of Signaling Interfaces -- PI3-Kinase Inhibition -- Src as a Target for Pharmaceutical Intervention -- Activated FLT3 Receptor Tyrosine Kinase as a Therapeutic Target In Leukemia -- JAK Kinases in Leukemias, Lymphomas, and Multiple Myeloma -- Glivec® (Gleevec®, Imatinib, STI571) -- Platelet-Derived Growth Factor -- Structural Biology of Protein Tyrosine Kinases -- Testing of Signal Transduction Inhibitors in Animal Models of Cancer -- Phosphoproteomics in Drug Discovery and Development.
520 ## - SUMMARY, ETC.
Summary, etc. Protein kinases function as components of signal transduction pathways, playing a central role in the control of cell growth, metabolism, differentiation, and apoptosis. The development of selective protein tyrosine kinase (PTK) inhibitors that can block or modulate diseases, such as cancer, with abnormalities in these signaling pathways is considered a promising approach for drug development. Currently, more than 20 different PTKs are being considered as potential therapeutic targets in oncology. In Protein Tyrosine Kinases: From Inhibitors to Useful Drugs, leading researchers from the Novartis group that pioneered Gleevec/Glivec™ and from around the world comprehensively survey the state-of-the-art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made toward generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing PTK inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors. Authoritative and state-of-the-art, Protein Tyrosine Kinases: From Inhibitors to Useful Drugs details the key stages in the design of PTK inhibitors and their development into useful drugs.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Life sciences.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Biochemistry.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Life Sciences.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Biochemistry, general.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Fabbro, Doriano.
Relator term editor.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name McCormick, Frank.
Relator term editor.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Relationship information Printed edition:
International Standard Book Number 9781588293848
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title Cancer Drug Discovery and Development
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier http://dx.doi.org/10.1385/1592599621
912 ## -
-- ZDB-2-SBL
Holdings
Withdrawn status Lost status Damaged status Not for loan Permanent Location Current Location Date acquired Barcode Date last seen Price effective from Koha item type
        PK Kelkar Library, IIT Kanpur PK Kelkar Library, IIT Kanpur 2016-11-21 EBK2728 2016-11-21 2016-11-21 E books

Powered by Koha